Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes

Despite increases in the availability and effectiveness of other therapies, insulin remains an essential treatment for approximately 30 million people with type 2 diabetes worldwide. The development of biosimilars has created the potential for significant health care cost savings and may lead to gre...

Descripción completa

Detalles Bibliográficos
Autores principales: Heller, Simon, Raposo, João Filipe, Tofé, Santiago, Hanif, Wasim, Schroner, Zbynek, Down, Su, Blevins, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2023
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115621/
https://www.ncbi.nlm.nih.gov/pubmed/37092154
http://dx.doi.org/10.2337/cd22-0016
_version_ 1785028248230428672
author Heller, Simon
Raposo, João Filipe
Tofé, Santiago
Hanif, Wasim
Schroner, Zbynek
Down, Su
Blevins, Thomas
author_facet Heller, Simon
Raposo, João Filipe
Tofé, Santiago
Hanif, Wasim
Schroner, Zbynek
Down, Su
Blevins, Thomas
author_sort Heller, Simon
collection PubMed
description Despite increases in the availability and effectiveness of other therapies, insulin remains an essential treatment for approximately 30 million people with type 2 diabetes worldwide. The development of biosimilars has created the potential for significant health care cost savings and may lead to greater access to basal insulin for vast populations. In this review, we discuss evidence demonstrating equipoise between basal insulin biosimilars and the patented analogs they may replace.
format Online
Article
Text
id pubmed-10115621
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-101156212023-06-15 Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes Heller, Simon Raposo, João Filipe Tofé, Santiago Hanif, Wasim Schroner, Zbynek Down, Su Blevins, Thomas Clin Diabetes Feature Articles Despite increases in the availability and effectiveness of other therapies, insulin remains an essential treatment for approximately 30 million people with type 2 diabetes worldwide. The development of biosimilars has created the potential for significant health care cost savings and may lead to greater access to basal insulin for vast populations. In this review, we discuss evidence demonstrating equipoise between basal insulin biosimilars and the patented analogs they may replace. American Diabetes Association 2023 2022-08-09 /pmc/articles/PMC10115621/ /pubmed/37092154 http://dx.doi.org/10.2337/cd22-0016 Text en © 2023 by the American Diabetes Association https://www.diabetesjournals.org/journals/pages/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.
spellingShingle Feature Articles
Heller, Simon
Raposo, João Filipe
Tofé, Santiago
Hanif, Wasim
Schroner, Zbynek
Down, Su
Blevins, Thomas
Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
title Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
title_full Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
title_fullStr Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
title_full_unstemmed Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
title_short Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
title_sort breaking barriers with basal insulin biosimilars in type 2 diabetes
topic Feature Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115621/
https://www.ncbi.nlm.nih.gov/pubmed/37092154
http://dx.doi.org/10.2337/cd22-0016
work_keys_str_mv AT hellersimon breakingbarrierswithbasalinsulinbiosimilarsintype2diabetes
AT raposojoaofilipe breakingbarrierswithbasalinsulinbiosimilarsintype2diabetes
AT tofesantiago breakingbarrierswithbasalinsulinbiosimilarsintype2diabetes
AT hanifwasim breakingbarrierswithbasalinsulinbiosimilarsintype2diabetes
AT schronerzbynek breakingbarrierswithbasalinsulinbiosimilarsintype2diabetes
AT downsu breakingbarrierswithbasalinsulinbiosimilarsintype2diabetes
AT blevinsthomas breakingbarrierswithbasalinsulinbiosimilarsintype2diabetes

Ejemplares similares